Target
BRCA2
26 products, 24 indications
Indications
Metastatic Castration-Resistant Prostate Cancer (5 products)
Platinum-sensitive recurrent ovarian carcinoma (4 products)
Advanced Epithelial Ovarian Cancer (3 products)
high grade serous ovarian carcinoma (2 products)
Ovarian Cancer (2 products)
Advanced high-grade ovarian cancer (2 products)
Platinum-resistant recurrent ovarian carcinoma (2 products)
metastatic hormone-resistant prostate cancer (1 products)
Endometrial and ovarian cancer (1 products)
advanced HER2 negative gastric, esophageal, and gastroesophageal junction adenocarcinoma (1 products)
Ovarian cancer, primary peritoneal cancer, fallopian tube cancer (1 products)
recurrent or metastatic head and neck squamous cell carcinoma (1 products)
recurrent or metastatic cervical cancer (1 products)
high-grade stage III/IV ovarian cancer (1 products)
metastatic hormone sensitive prostate cancer (1 products)
recurrent high-grade ovarian, fallopian tube and primary peritoneal cancer (1 products)
Recurrent PARPi-resistant ovarian cancer (1 products)
platinum-resistant/refractory epithelial ovarian cancer (1 products)
relapsed/refractory NSCLC (1 products)
platinum-resistant high-grade serous ovarian cancer (1 products)
HRD-positive recurrent platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
glioblastoma (1 products)
Loading...
1 drug
133 abstracts
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.Org: Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Division of Clinical Cancer Genomics, Hokkaido University Hospital, Hokkaido, Japan, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,
Abstract
PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study.Org: McGill University Health Center, Jewish General Hospital Stroll Cancer Prevention Centre, Montréal, QC, Canada, McGill University Department of Human Genetics, Montreal, QC, Canada,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.Org: Department of Medical Oncology, Erasmus Medical Cancer Institute, Rotterdam, Netherlands, Radboud University Medical Center, Nijmegen, Netherlands, Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands, Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands, Department of medical oncology, Leiden University Medical Center, Leiden, Netherlands,
Abstract
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.Org: Foundation Medicine, Inc., Cambridge, MA, Cedars-Sinai Medical Center, SUNY Upstate Medical University, University of California, San Diego Health,
Abstract
Rapid label expansion based on public-private collaboration in IMPRESS-Norway.Org: Oslo University Hospital-Norwegian Radium Hospital, Department of Cancer Immunology, The Arctic University of Norway, Centre for Cancer Biomarkers CCBIO,
Abstract
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).Org: Department of Urology, University of California, San Diego,
Abstract
Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecologic Oncology, Cancer Hospital of The University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, Department of Gynecologic Oncology, Anhui Provincial Cancer Hospital, Hefei, China, Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China,
Abstract
Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Pfizer Oncology Global Medical Affairs,
Abstract
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).Org: Department of Quantitative Science Research, Mount Sinai Comprehensive Cancer Center, University of California, San Diego Moores Cancer Center, Inova Fairfax Medical Campus, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).Org: Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Apmonia Therapeutics, CNRS UMR 7369 MEDyC - Reims University,
Abstract
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,
Abstract
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.Org: Breast Medicine Service,
Abstract
Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study.Org: Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany, Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany, Hospital Aschaffenburg GmbH, Aschaffenburg, Germany, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany,
Abstract
Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer.Org: Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Pathways for provider initiated genetic testing to bridge the gap in germline genetic testing for metastatic breast cancer.Org: The University of Texas Health Science Center at Houston, McGovern Medical School, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Insights from C-CAT repository: A novel approach to identifying appropriate patient populations for anticancer drug development using the clinicogenomic nationwide database in Japan.Org: National Cancer Center Research Institute, National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East,
Abstract
A systematic review of racial disparity in pivotal poly (ADP-ribose) polymerase (PARP) inhibitor trials.Org: University of Tennessee Health Science Center, Memphis, TN, University of Tennessee Health Science Center, Piperton, TN,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Association of homologous recombination repair mutation defined with a 15-gene panel with the prognosis of epithelial ovarian cancer: A Chinese multicenter retrospective study.Org: The Affiliated Zhongda Hospital, Southeast University, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University,
Abstract
A systematic literature review and indirect treatment comparison of PARP inhibitors in combination with next-generation hormonal agents in BRCA-mutated metastatic castration‑resistant prostate cancer.Org: Mtech Access,
Abstract
Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment in patients with metastatic gastric cancer (mGC).Org: Idience Inc.,
Abstract
Germline alterations in patients with lung cancer.Org: Tempus Labs, Inc., Washington University School of Medicine, Washington University in Saint Louis,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.Org: Janssen, Janssen Pharmaceuticals, Janssen Research & Development, Janssen-Cilag B.V., Janssen Pharmaceutica NV,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
Breast cancer risk associated with missense variants in BRCA2.Org: Ambry Genetics, Harvard T.H. Chan School of Public Health, Sierra Madre, Abramson Cancer Center, University of Pennsylvania,
Abstract
Germline genetic testing use and results after a cancer diagnosis.Org: Stanford University School of Medicine, Stanford Women's Cancer Center, GeneDx, Myriad Genetics, Stanford Cancer Institute,
Abstract
High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.Org: The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Rijnstate Hospital, Ziekenhuis ZGT Hengelo, Amphia Hospital,
Abstract
Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer.Org: Guardant Health Inc., Guardant Health, Inc.,
Abstract
Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.Org: Centre Léon Berard, UNIV Lyon-Université Claude Bernard Lyon 1, Genotypos M.S.A., Genotypos Science Labs, AGO Study Group & Ev. Kliniken Essen-Mitte,
Abstract
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, New York, NY, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College,
Abstract
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Tempus Labs, Inc., Johns Hopkins University Bloomberg School of Public Health, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Olaparib (O) + ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial.Org: AstraZeneca, University Hospitals Leuven, Leuven, Belgium, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Seoul National University College of Medicine, Christie Hospital NHS Foundation Trust and the University of Manchester,
Abstract
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Prevalence of unexpected actionable germline pathogenic variants identified on broad-based multi-gene panel testing in a cohort of cancer patients.Org: University of Vermont Larner College of Medicine, Dana-Farber Cancer Institute,
Abstract
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.Org: Breast Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service,
Abstract
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).Org: Yale School of Medicine, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Alternative allele frequency recallibration after NGS data analysis.Org: OncoAtlas LLC, Atlas Oncodiagnostics, N.N. Blokhin Russian Cancer Research Center,
Abstract
Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.Org: Genome Insight Inc., Research Institute for Future Medicine, Division of Breast Surgery, Division of Breast and Endocrine Surgery, Samsung Medical Center,
Abstract
ctDNA detection in patients with brain metastases arising from solid tumors.Org: Duke University Medical Center, Department of Biostatistics & Bioinformatics & CALGB Statistical Center, Duke Cancer Institute, Duke University Cancer Institute, Dana-Farber Cancer Institute,
Abstract
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.Org: Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Foundation Medicine, Inc., Cambridge, MA, Stephenson Cancer Center at the University of Oklahoma HSC, University of Okahoma Health Sciences Center,
Abstract
Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.Org: Tempus Labs, Inc., University of Pennsylvania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Clinical implications of molecular alterations in intraductal carcinoma of the prostate.Org: Fox Chase Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Caris Life Sciences, Irving, TX, Oncologia D`Or, A.C. Camargo Cancer Center,
Abstract
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.Org: Foundation Medicine, Inc., Cambridge, MA, Mayo Clinic, Foundation Medicine Inc, Morrisville, NC,
Abstract
Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Ramón y Cajal University Hospital, Madrid, Spain, Cardiology Department, Biochemistry Department,
Abstract
Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.Org: Gynecologic Medical Oncology Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).Org: Harvard Medical School, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center, Houston, TX,
Abstract
Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Duke University Medical Center, NRG Oncology, University of Iowa Hospitals and Clinics,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Retrospective evaluation of the value of DNA damage repair gene signature in response to platinum-based chemotherapy in advanced pancreatic ductal adenocarcinoma.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital General de Granollers, Hospital Universitari Vall d'Hebron Research Institute,
Abstract
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.Org: Epic Sciences, Inc., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Molecular Imaging and Therapeutic Nuclear Medicine,
Abstract
Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Perthera, Oregon Health & Science University, Pancreatic Cancer Action Network, Cedars-Sinai Medical Center,
Abstract
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.Org: Dana-Farber Cancer Institute, University College London Cancer Institute, South Australian Immunogenomics Cancer Institute,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).Org: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, H. Universitario Reina Sofía, Universidad de Córdoba, Hospital Universitario Miguel Servet, CIBERONC-ISCIII,
Abstract
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, UCLA's Jonsson Comprehensive Cancer Center, West Los Angeles VA Medical Center, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.Org: Johns Hopkins University Bloomberg School of Public Health, University of Nebraska Medical Center, Allegheny Health Network Cancer Institute - AGH, Thomas Jefferson University Hospital, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine,
Abstract
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).Org: Biomedical Statistics Center, Samsung Medical Center, Seoul, South Korea, Department of Biomedical Science, CHA university, Seongnam, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Center for Gynecologic Cancer, National Cancer Center, Ilsandong-Gu, Goyang-Si, South Korea, Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore,
Abstract
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Swedish Cancer Institute, American Society of Clinical Oncology, Sutter Sacramento Medical Center, Cancer Treatment Centers of America – Chicago, part of City of Hope, Michigan Cancer Research Consortium,
Abstract
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Herbert-Herman Cancer Center, Michigan Cancer Research Consortium, American Society of Clinical Oncology, Cancer Treatment Centers of America – Chicago, part of City of Hope, Levine Cancer Institute,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
African American women who carry the BRCA1/2 mutation: Clinical characteristics and prevention strategies.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, Beaumont Health, Oakland University William Beaumont Medical School,
Abstract
Investigation of cancer predisposition in Fanconi anemia heterozygotes: A DiscovEHR cohort population study.Org: National Cancer Institute, Vilnius, Lithuania, Geisinger Medical Center,
Abstract
Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.Org: Vanderbilt University Medical Center, Meharry Medical College, Nihon Medi-Physics, Vanderbilt-Ingram Cancer Center,
Abstract
Frequency of pathogenic germline variants in cancer susceptibility genes in 841 renal cell carcinoma cases.Org: AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,
Abstract
Clinical factors associated with successful liquid tumor biopsy in men with prostate cancer.Org: Department of Veterans Affairs James Hailey Hospital, University of California Los Angeles, US Department of Veterans Affairs, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington Medical Center,
Abstract
Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
Implementation of universal pan-cancer germline genetic testing in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.Org: King Hussein Cancer Center, Invitae, King Hussein Medical Center,
Abstract
Hereditary breast and ovarian cancer syndrome: A misnomer?Org: New York Medical College - Saint Michael's Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.Org: University of Texas Medical Branch at Galveston, University of Texas MD Anderson Cancer Center,
Abstract
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.Org: Invitae, Lee Kong Chian School of Medicine, Nanyang Technological University, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.Org: Johns Hopkins University School of Medicine, University of Texas MD Anderson Cancer Center, University of Pennsylvania, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, University of Texas at MD Anderson Cancer Center,
Abstract
Comprehensive multi-omic testing from a single laboratory to provide information in ovarian cancer.Org: Myriad Genetics, Inc., Myriad Genetic Laboratories, Inc.,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Trends in the needs and clinical utility of comprehensive genomic profiling test in rare cancers before and after the National Health Insurance coverage in Japan.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Research Institute,
Abstract
A population-based study of BRCA breast cancer incidence and prognosis in the Italian Emilia Romagna region: The MUTina study.Org: University Hospital Modena, University Hospital of Parma, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Azienda USL-IRCCS, City Hospital,
Abstract
Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Instituto Nacional de Cancerologia, Instituto Nacional de Medicina Genómica, Facultad de Medicina del Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico,
Abstract
Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.Org: Taipei Veterans General Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.Org: National University Cancer Institute, National University Hospital, Icon Cancer Centre, NUHS,
Abstract
Validation of a breast cancer polygenic risk score in 15,490 Brazilians using exome sequencing.Org: Mendelics, Instituto D’Or de Pesquisa e Ensino (IDOR), Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, The University of Chicago Medicine Center for Advanced Care at Orland Park, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts.Org: Invitae, Mayo Clinic, Mayo Clinic Cancer Center Scottsdale, Mayo Clinic in Arizona, Division of Gastroenterology and Hepatology, Mayo Clinic,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Utilization of germline testing in patients with early-onset pancreatic cancer (EOPC).Org: Atrium Health Levine Cancer Institute, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Levine Cancer Institute, Atrium Health Carolinas Medical Center,
Abstract
Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Bayindir Sogutozu Hospital, Istanbul University Dep of Oncology, Hacettepe University Faculty of Medicine Department of Medical Oncology, Istanbul University Cerrahpasa Faculty of Medicine,
Abstract
Commercial next generation sequencing in a real-world cohort of patients with metastatic breast cancer.Org: Renaissance School of Medicine at Stony Brook University, Stony Brook University Hospital - Cancer Center,
Abstract
Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Genomic profiling of biliary tract carcinomas by their location.Org: Exact Sciences Corporation, Phoenix, AZ, Redwood City, CA, Houston Methodist Cancer Center, Houston, TX,
Abstract
Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.Org: 3D Medicines Inc.,
Abstract
Impact of early testing and analysis of germline genetic mutation patterns in patients with breast cancer: A single institution experience.Org: Mercy Clinic Oncology- Fort Smith, Fort Smith, Arcus Biosciences,
Abstract
Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants.Org: University of Kentucky Markey Cancer Center, University of Kentucky Chandler Medical Center, University of Kentucky, Lexington, KY, Department of Pathology and Laboratory Medicine University of Kentucky Chandler Medical Center, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Kentucky College of Medicine,
Abstract
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea,
Abstract
Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd Nanjing, China, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Somatic hereditary gene panel analysis: A pilot study from Uzbekistan.Org: Vita Alliance Hospital, Tashkent, Uzbekistan,
Abstract
Survival outcomes of BRCA1/BRCA2 mutated breast cancers: Study from a tertiary care cancer centre in India.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, BRA-IRCH, National Cancer Institute, Vilnius, Lithuania, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.Org: Medical University of South Carolina Hollings Cancer Center, Institut Català d’Oncologia L’Hospitalet de Llobregat, Hospital Duran i Reynals, IDIBELL, Grupo Español de Investigación en Cáncer de Ovario (GEICO),
Abstract
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.Org: Hospital Privado Universitario de Córdoba, CIMETSA-IUCBC,
Abstract
Homologous recombination-related (HRR) gene mutations in patients with glioma and their relevance to genomic characteristics, tumor mutation burden (TMB), and prognosis.Org: Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Prevalence of BRCA1 and BRCA2 mutations in an unselected cohort of Indian women with breast cancer.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Surgical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, National Cancer Institute-All India Institute of Medical Science (AIIMS),
Abstract
Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Genetic counseling referral frequency and attrition for newly diagnosed epithelial ovarian cancer at Grady Memorial Hospital from 2012-2022.Org: Emory University Hospital, Winship Cancer Center of Emory University, Emory University School of Medicine, Grady Memorial Hospital,
Abstract
Spectrum of germline pathogenic variants among patients with cancer in Mexico.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, National Institute of Medical Sciences and Nutrition Salvador Zubirán, City of Hope National Medical Center, Latin American School of Oncology,
Abstract
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.Org: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy, Department of Surgical Oncological and Oral Sciences, Palermo, Italy, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy, Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy, Azienda Ospedaliera Universitaria "P.Giaccone", Palermo, Italy, Department of Surgical Oncological and Oral Sciences; University of Palermo, Palermo, Italy, Proteomics Group of Fondazione Ri.MED, Department of Research IRCCS ISMETT, 90145 Palermo, Italy, Palermo, Italy, University School of Medicine, Palermo, Italy, A.O.U. Policlinico P. Giaccone, Palermo, Italy, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy, Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, University of Palermo, Palermo, Italy,
Abstract
Comparison of BRCA genetic testing and subsequent treatment with PARP inhibitors (PARPi) for ederly vs non-elderly women with non-mucinous epithelial ovarian cancer (EOC): A large prospective cohort study from the Australian National Gynaecology Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Women's Hospital, Epworth Healthcare, Monash University School of Public Health and Preventive Medicine and Department of Medical Oncology, Alfred Health,
Abstract
Tumor sensitization to PARP inhibitors by DNA damaging synthetically lethal acylfulvenes.Org: Lantern Pharma,
Abstract
The impact of next generation sequencing on the management of urothelial cell carcinoma.Org: Long Island Jewish Forest Hills, Forest Hills Lab, Long Island Jewish Medical Center, Queens, NY, Northwell Health, New Hyde Park, NY,
Abstract
Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, National Hospital Organization Shikoku Cancer Center, Department of Gastroenterology, Saitama Cancer Center, Saitama-Shi, Japan, Kanagawa Cancer Center,
Abstract
Reliance of agency-approved and guideline-recommended therapies on surrogate endpoints in triple-negative breast cancer (TNBC).Org: The Larvol Group, LLC, Labcorp Drug Development Inc., Princeton, NJ, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust,
Abstract
The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.Org: Department of Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China, Department of Gynecology, The 980th Hospital of the PLA Joint Logistic Support Force, Shijiazhuang, China, Yinfeng Gene Technology Co Ltd, Jinan, China, Clinical Oncology Research Alliance, Tianjin, China,
Abstract
Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.Org: Cukurova University Medical Faculty Medical Genetics Department, Cukurova University AGENTEM, InfoGenom R&D Laboratories, University of Kentucky Biology Department, Baskent University Hospital,
Abstract
BRCA mutations in triple negative breast cancer patients in Guatemala: A descriptive study.Org: Liga Nacional Contra El Cancer e Instituto de Cancerologia-INCAN, Guatemala, Guatemala, Instituto de Cancerologia-INCAN,
Abstract
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.Org: Yemaachi Biotech, Cape Coast Teaching Hospital, University of Cape Coast, Lucence Diagnostics Pte Ltd, Lucence Health Inc,
Abstract
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.Org: Arima Genomics, Scripps Clinic/Green Hospital, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Scripps Clinic and Scripps MD Anderson Cancer Center,
Abstract
Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer.Org: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai OrigiMed Co., Ltd., Shanghai, China,
Abstract
The landscape of ATM alteration in Chinese solid tumor patients.Org: Ya’an People’s Hospital, Yinfeng Gene Technology Co Ltd, Huaxi Kindstar Medical Diagnostics (Sichuan) Co Ltd, Clinical Oncology Research Alliance,
Abstract
Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, Research Triangle Park, NC,
Abstract
Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM).Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Integra Connect PrecisionQ, Illumina, Inc., Integra Connect,
Abstract
Comprehensive analysis of the mutational status of early colon cancer: Real world data from the AIO ColoPredict registry study.Org: Institut für Pathologie, Georgius Agricola Stiftung Ruhr, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Oncology and Palliative Care Units, Ruhr-University Bochum,
Abstract
Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).Org: Merck & Co., Inc., Merck and Co., Inc, Integra Connect PrecisionQ,
Abstract
Clinical implications of universal germline testing in breast cancer patients in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.Org: King Hussein Cancer Center, Amman, Jordan, Invitae, San Francisco, CA, King Hussien Cancer Center,
Abstract
Accuracy of a simplified sequencing and bioinformatics platform on genetic variant detection in patients with prostate cancer.Org: Icahn School of Medicine at the Mount Sinai Hospital, Integrated Medical Professionals, PLLC,
Abstract
High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.Org: The First People's Hospital of Foshan, Foshan First People's Hospital, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd,
Abstract
Measuring real-world concordance with evidence-based guidelines for genetic testing in patients with breast cancer: A retrospective quality review.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Clinical characteristics, response to poly (adenosine phosphate-ribose) polymerase inhibitors and platinum chemotherapy in patients with lung cancer harboring BRCA mutations.Org: Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel, Ein Kerem, Factuality of Medicine,
Abstract
Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Real-world genetic testing patterns in metastatic prostate cancer in Latin American (LATAM) population.Org: Instituto Alexander Fleming, Fundación Cancer - Fuca, Hospital Italiano de Buenos Aires, Sociedad de Oncología y Hematología del Cesar SOHEC, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru,
Drug
Olaparib